Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBT Margin (2022 - 2025)

Atara Biotherapeutics' EBT Margin history spans 4 years, with the latest figure at 213.54% for Q4 2025.

  • For Q4 2025, EBT Margin fell 17505.0% year-over-year to 213.54%; the TTM value through Dec 2025 reached 27.09%, up 9325.0%, while the annual FY2025 figure was 27.09%, 9325.0% up from the prior year.
  • EBT Margin reached 213.54% in Q4 2025 per ATRA's latest filing, down from 123.81% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 38.73% in Q1 2025 to a low of 33742.08% in Q4 2022.
  • Average EBT Margin over 4 years is 3718.37%, with a median of 168.67% recorded in 2025.
  • The largest YoY upside for EBT Margin was 3229333bps in 2023 against a maximum downside of -900264bps in 2023.
  • A 4-year view of EBT Margin shows it stood at 33742.08% in 2022, then soared by 96bps to 1448.75% in 2023, then surged by 97bps to 38.49% in 2024, then crashed by -455bps to 213.54% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EBT Margin are 213.54% (Q4 2025), 123.81% (Q3 2025), and 13.6% (Q2 2025).